Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib

Clinical Pharmacology: Advances and Applications

Volumn 6, Issue 1, 2014, Pages 87-96

  Harvey, R Donald ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Adverse events; Carfilzomib; Myeloma; Refractory; Relapsed; Safety; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARFILZOMIB; CREATININE;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANEMIA; BACKACHE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFUSION RELATED REACTION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 84900422460     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S62512     Document Type: Review

References (35)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-339.
2. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219-9226.
3. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49: 1211-1225.
4. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17: 1264-1277.
5. Laubach J, Mitsiades MCS, Mahindra A, et al. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011;9:1209-1216.
6. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111: 2516-2520.
7. Pingali SR, Haddad RY, Saad A. Current concepts of clinical management of multiple myeloma. Dis Mon. 2012;58:195-207.
8. Robin J, Fintel B, Pikovskaya O, Davidson C, Cilley J, Flaherty J. Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature. J Med Case Rep. 2008;2:229.
9. Chow AW, Lee CH, Hiwase DK, To LB, Horvath N. Relapsed multiple myeloma: who benefits from salvage autografts? Intern Med J. 2013;43:156-161.
10. Onyx Pharmaceuticals, Inc. Kyprolis® (carfilzomib) prescribing information. South San Francisco, CA, USA; Onyx Pharmaceuticals, Inc.; 2012.
11. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817-2825.
12. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. Haematologica. 2013;98:1753-1761.
13. Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12:310-318.
14. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158:739-748.
15. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119:5661-5670.
16. Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27:1707-1714.
17. ClinicalTrials. gov. Phase 2 study of carfilzomib in relapsed and refractory multiple myeloma. Available from: http://clinicaltrials.gov/show/NCT00511238. Accessed November 6, 2013.
18. ClinicalTrials. gov. Phase 2 study of carfilzomib in relapsed multiple myeloma. Available from: http://clinicaltrials.gov/show/NCT00530816. Accessed November 6, 2013.
19. ClinicalTrials. gov. Study of the safety and pharmacokinetics of carfilzomib in subjects with relapsed and refractory multiple myeloma and varying degrees of renal function. Available from: http://clinicaltrials.gov/show/NCT00721734. Accessed November 6, 2013.
20. Nooka A, Badros A, Patel P, McCulloch L, Lonial S, Kaufman J. Hematologic safety data from four phase 2 studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma. Abstract (8086) and poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012, Chicago, IL, USA.
21. Common Terminology Criteria for Adverse Events version 3.0. Bethesda, MD, USA: US National Institute of Health, National Cancer Institute, Cancer Therapy Evaluation Program; 2006. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_index.pdf. Accessed March 12, 2014.
22. McBride L, Samuel C. The side effect profile of carfilzomib: from clinical trials to clinical practice. J Adv Pract Oncol. 2013;4:22-30.
23. Redic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol. 2013;65:1095-1106.
24. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24: 3187-3205.
25. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.
26. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2013;11:1266-1290.
27. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012;120:4505-4512.
28. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor study. Blood. 2007;109:1765-1772.
29. Kistler KD, Rajangam K, Faich G, Lanes S. Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood. 2012;120:Abstr 2916.
30. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-2247.
31. Lonial S, Niesvizky R, McCulloch L, Rajangam K, Vij R. Cardiac and pulmonary safety profile of single-agent carfilzomib from four phase 2 studies in patients with relapsed and/or refractory multiple myeloma. Abstract (4037) and poster presented at the Annual Meeting of the American Society of Hematology, December 8-11, 2012, Atlanta, GA, USA.
32. Harvey R, Lonial S, Wong A, McCulloch L, Badros A, Kaufman J. Renal safety profile of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma from four phase 2 studies. Abstract and poster presented at Lymphoma and Myeloma Congress, October 25-27, 2012; New York, NY, USA.
33. Martin T, Vij R, Badros AZ, Patel P, McCulloch L, Jagannath S. Carfilzomib is associated with a low rate of typically mild to moderate, non-dose limiting treatment-emergent peripheral neuropathy. Abstract 0857 and poster presented at Annual Meeting of the European Hematology Association, June 14-17, 2012, Amsterdam, The Netherlands.
34. Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006;7:233-235.
35. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854.